Soft tissue sarcomas prognosis based on clinical-pathological profile: a retrospective population-based study

Abstract

Soft tissue sarcomas (STSs) account for less than 1% of adult cancers and encompass a diverse range of neoplastic diseases. This population-based study evaluates the five-year overall survival rates of a cohort of STS patients. The study examined 325 incident cases of nonmetastatic STS recorded by the population-based Veneto Regional Cancer Registry in 2017 and 2018. The association between demographics, clinical-pathological features, and survival rates was assessed using the Kaplan-Meier method and Cox regression analysis. The five-year overall survival was 73.2% (95%CI: 68.5–78.2). Retroperitoneal STSs showed the highest mortality risk (HR = 3.18, 95% CI: 1.53–6.61; p = 0.002). The line of STS differentiation (Fibroblastic/myo-fibroblastic: HR = 2.86, 95%CI: 1.3–6.28, p = 0.009) emerged as independent prognostic factors. Patients’ sex ( p = 0.026), age ( p < 0.001), and stage ( p < 0.001) were significant predictor. In this population-based study, the clinical outcomes of STS patients were significantly associated with patient age, primary site, and histology subtype. The diverse outcomes of STS histotypes emphasize the importance of multicenter, large-scale studies based on consensus diagnostic criteria within the histological lines of differentiation.